Ardelyx (ARDX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 May, 2026Executive summary
Proposal to amend the 2014 Equity Incentive Award Plan by adding 9,000,000 shares to the reserve, supporting growth and talent retention through 2027.
The amendment is positioned as essential for scaling operations, commercializing products, and building the pipeline.
Forward-looking statements highlight plans for continued growth, commercialization, and pipeline development, with risks noted regarding talent competition and capital resources.
Voting matters and shareholder proposals
Stockholders are asked to approve the amendment to the equity plan at the June 16, 2026 annual meeting.
The Board of Directors, after review with independent advisors, strongly recommends voting in favor of the proposal.
Board of directors and corporate governance
The Compensation and Leadership Development Committee conducted a thorough evaluation and recommended the equity plan amendment to the Board.
Directors, officers, and employees may be participants in the proxy solicitation, with their interests disclosed in the proxy statement.
Latest events from Ardelyx
- Q2 2026 revenue up 31% to $118.1M; net loss narrows, guidance updated for market shifts.ARDX
Q2 2026 - IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029.ARDX
Jefferies Global Healthcare Conference 2026 - Board seeks approval to expand equity plan, supporting growth and talent retention through 2027.ARDX
Proxy filing - IBSRELA targets $1B+ sales by 2029, with pipeline and cash flow fueling future growth.ARDX
Leerink Global Healthcare Conference 2026 - Q3 2025 revenue up 12% to $110.3M, led by IBSRELA's 92% growth and strong liquidity.ARDX
Q3 2025 - Q3 revenue surged 74% year-over-year, led by strong IBSRELA and XPHOZAH sales.ARDX
Q3 2024 - TDAPA application was declined to protect XPHOZAH access as legislative solutions are pursued.ARDX
Business Update - Q1 revenue surged 61% to $74.1M, but net loss widened to $41.1M on higher expenses.ARDX
Q1 2025 - 2024 revenue hit $333.6M, net loss narrowed, and cash rose to $250.1M, supporting future growth.ARDX
Q4 2024